|Bid||0.00 x 20000|
|Ask||0.00 x 20000|
|Day's Range||49.07 - 49.07|
|52 Week Range||47.91 - 69.24|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||7.80|
|Forward Dividend & Yield||1.70 (3.52%)|
|Ex-Dividend Date||Jul 22, 2020|
|1y Target Est||N/A|
You could add either of these giants to your portfolio, sit back, and watch the gains trickle in -- even in the worst of times.
These two healthcare stocks both have their advantages now, but one may be better poised for steady growth.
The big pharma stock is available at a discount primarily because investors aren't sure how AbbVie will perform once its top-selling drug Humira begins to face biosimilar rivals in the U.S. beginning in 2023. Rinvoq won Food and Drug Administration (FDA) approval last year for treating rheumatoid arthritis, while Skyrizi scored FDA approval for treating plaque psoriasis. AbbVie is evaluating both drugs in late-stage studies targeting other autoimmune diseases, as well.